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Abstract
BACKGROUND
Hepatitis delta virus (HDV) seems to strongly suppress hepatitis B virus (HBV)
replication, although little is known about the mechanism of this interaction. Both
these viruses show a dynamic distribution of mutants, resulting in viral
quasispecies. Next-generation sequencing is a viable approach for analyzing the
composition of these mutant spectra. As the regulatory hepatitis B X protein
(HBx) is essential for HBV replication, determination of HBV X gene (HBX)
quasispecies complexity in HBV/HDV infection compared to HBV mono-
infection may provide information on the interactions between these two viruses.
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AIM
To compare HBV quasispecies complexity in the HBX 5’ region between chronic
hepatitis delta (CHD) and chronic HBV mono-infected patients.
METHODS
Twenty-four untreated patients were included: 7/24 (29.2%) with HBeAg-
negative chronic HBV infection (CI, previously termed inactive carriers), 8/24
(33.3%) with HBeAg-negative chronic hepatitis B (CHB) and 9/24 (37.5%) with
CHD. A serum sample from each patient was first tested for HBV DNA levels.
The HBX 5’ region [nucleotides (nt) 1255-1611] was then PCR-amplified for
subsequent next-generation sequencing (MiSeq, Illumina, United States). HBV
quasispecies complexity in the region analyzed was evaluated using incidence-
based indices (number of haplotypes and number of mutations), abundance-
based indices (Hill numbers of order 1 and 2), and functional indices (mutation
frequency and nucleotide diversity). We also evaluated the pattern of nucleotide
changes to investigate which of them could be the cause of the quasispecies
complexity.
RESULTS
CHB patients showed higher median HBV-DNA levels [5.4 logIU/mL,
interquartile range (IQR) 3.5-7.9] than CHD (3.4 logIU/mL, IQR 3-7.6) (P = n.s.)
or CI (3.2 logIU/mL, IQR 2.3-3.5) (P < 0.01) patients. The incidence and
abundance indices indicated that HBV quasispecies complexity was significantly
greater in CI than CHB. A similar trend was observed in CHD patients, although
only Hill numbers of order 2 showed statistically significant differences (CHB
2.81, IQR 1.11-4.57 vs CHD 8.87, 6.56-11.18, P = 0.038). There were no significant
differences in the functional indices, but CI and CHD patients also showed a
trend towards greater complexity than CHB. No differences were found for any
HBV quasispecies complexity indices between CHD and CI patients. G-to-A and
C-to-T nucleotide changes, characteristic of APOBEC3G, were higher in CHD and
CI than in CHB in genotype A haplotypes, but not in genotype D. The proportion
of nt G-to-A vs A-to-G changes and C-to-T vs T-to-C changes in genotype A and
D haplotypes in CHD patients showed no significant differences. In CHB and CI
the results of these comparisons were dependent on HBV genotype.
CONCLUSION
The lower-replication CHD and CI groups show a trend to higher quasispecies
complexity than the higher-replication CHB group. The mechanisms associated
with this greater complexity require elucidation.
Key words: Hepatitis B virus; Hepatitis delta virus; Hepatitis B X gene; Next-generation
sequencing; Viral quasispecies; Hepatitis B virus-hepatitis delta virus interaction
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Hepatitis B virus (HBV) replication is lower in the presence of hepatitis delta
virus (HDV), but little is known about the mechanism of this interaction. HBV X gene
quasispecies study in HBV/HDV infection could provide data regarding this interaction.
With use of next-generation sequencing, we analyzed HBV quasispecies complexity and
found a trend to greater complexity in chronic HDV and chronic HBV infection (CI,
previously termed inactive carriers) than in chronic hepatitis B. This suggests that HDV
may drive the HBV quasispecies to acquire a situation of diversity similar to that of CI
patients.
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INTRODUCTION
An estimated 257 million people worldwide are chronically infected with hepatitis B
virus (HBV), and 15 to 20 million of them are also infected with hepatitis delta virus
(HDV)[1].  HDV is a defective RNA virus that requires the helper function of HBV
surface antigen (HBsAg) to achieve transmission[2]. HDV infection can occur as an
acute  coinfection  (simultaneous  HBV/HDV  infection)  or  as  a  superinfection  in
individuals already chronically infected with HBV[3]. Acute HBV/HDV coinfection is
usually self-limited and shows a course similar to that of acute HBV mono-infection,
with clearance rates of both agents greater than 95% in immunocompetent adults.
Nonetheless, it can also cause severe acute hepatitis with a high-risk of developing a
fulminate course[4].  In superinfections,  HDV progresses to chronicity in > 80% of
cases[4]. Chronic HDV infection leads to more severe liver disease than chronic HBV
mono-infection. In fact, it is the most severe form of viral hepatitis in humans, with
accelerated  progression  of  fibrosis,  a  slightly  increased  risk  of  hepatocellular
carcinoma (HCC), and early decompensation in the setting of established cirrhosis[2].
HBV is an enveloped DNA virus consisting of a 3.2-kb partially double-stranded
genome that replicates via an RNA intermediate[5] and encodes 7 proteins: PreCore,
core, pol, X (HBx), and the three envelope proteins, L, M, and S. The HDV genome is
comprised of a 1.7-kb single-stranded circular RNA of negative polarity, the smallest
among known mammalian viruses[6]. As HDV does not encode an RNA-dependent
RNA polymerase, its replication relies on the host cell’s RNA polymerase II (RNA pol
II)[7].  The  HDV  genome  contains  a  single  functional  open  reading  frame  (ORF)
encoding  hepatitis  delta  antigen  (HDAg).  Through  the  action  of  RNA-specific
adenosine  deaminase  1  (ADAR  1)  editing  during  replication,  HDV  manages  to
produce two HDAg isoforms from this single ORF: The small (S-HDAg) and large (L-
HDAg) delta antigens. As compared to S-HDAg, L-HDAg contains 19 additional
amino acids at the C terminus[7]. Remarkably, the two HDAg isoforms have different
functions: S-HDAg binds to HDV RNA and promotes HDV replication, whereas L-
HDAg inhibits replication and is known to be involved in HDV packaging by direct
binding to HBsAg[8]. As the two viruses use the same envelope proteins, HDV and
HBV share common attachment and entry steps. Direct contact between HBsAg and
HDAg for HDV virion envelopment is considered the main interaction[9], but the two
viruses must also interact with each other at different stages of their replication cycles.
For example, previous studies have shown that HDV can strongly suppress HBV
replication and become the predominant virus in HBV/HDV infection[10,11]. However,
other patterns of predominance are also seen in HBV/HDV infection, related to the
fluctuating patterns of HBV and HDV replication over time[12].  Currently, little is
known about the specific mechanisms of this interaction. It has been suggested that
the suppressive effect of HDV on HBV replication may be mediated by the interaction
of HDAg with HBV enhancers[13], the L-HDAg-RNA pol II interaction[14], or by the
antiviral activity of interferon-inducible MxA protein activated by L-HDAg[13].
As  is  the  case  of  other  RNA  and  DNA  viruses  that  replicate  by  low-fidelity
polymerases, HDV and HBV both exhibit high mutation rates, and their populations
show a dynamic distribution of mutants.  This characteristic results in a complex
swarm of  sequences  that  are  highly  similar,  but  not  identical,  known as  a  viral
quasispecies[15,16]. Next-generation sequencing (NGS), also referred to as massive or
deep sequencing, is an ideal approach to analyze the composition and complexity of
the mutant spectra within a viral quasispecies[17,18]. This information can explain or
predict  the  response  of  the  virus  to  specific  environmental  changes.  The  HBV
quasispecies in chronic mono-infection and the HDV quasispecies have been analyzed
individually by NGS[19-23]. However, there are no studies comparing the quasispecies
in  HBV  mono-infection  and  HBV/HDV  infection  using  this  technique.
Characterization of the HBV population in each of these situations could provide
valuable information on the interference between HBV and HDV. The pleiotropic,
trans-activating HBx protein has an important role in regulating the HBV life cycle,
host-virus interactions, and HBV-related HCC[24], and HDV/HBV interactions at this
level may impair HBV replication/transcription. Therefore, the hepatitis B X gene
(HBX) could be an interesting target to study potential interactions between these two
viruses.
The aim of this study was to evaluate and compare the complexity of the HBV
quasispecies  in  serum samples  from HBV mono-infected patients  in  the chronic
infection phase (CI, previously termed inactive carrier), patients with chronic hepatitis
B  (CHB)  mono-infection,  and  patients  with  chronic  hepatitis  delta  (CHD)
superinfection, using a high-throughput NGS-based approach. We focused our study
on  the  5’  end  of  the  HBX  coding  region  and  its  upstream  non-coding  region
[nucleotides (nt) 1255-1611], which was also examined in a previous study by our
group in patients in different stages of chronic HBV infection, including CHB and
WJG https://www.wjgnet.com April 7, 2019 Volume 25 Issue 13
Godoy C et al. HBX gene complexity in HBV/HDV infection
1568
CI[23].
MATERIALS AND METHODS
Patients and samples
Twenty-four patients with chronic HBV infection in two different clinical  stages
including some with HDV superinfection were recruited from the outpatient clinics of
Vall d’Hebron University Hospital (Barcelona, Spain). According to the guidelines of
the European Association for the Study of the Liver[25], patients were classified into
three groups: Hepatitis B e-antigen (HBeAg)-negative CI (7 patients, 29.2%), HBeAg-
negative  CHB (8  patients,  33.3%),  and  CHD (9  patients,  37.5%).  The  study  was
approved  by  the  Ethics  Committee  of  Vall  d’Hebron  Research  Institute  and  all
patients provided written informed consent for participation.
One serum sample from each patient with HBV DNA ≥ 2.5 logIU/mL (sensitivity
limit of the PCR to amplify the target region) was selected for the study. Exclusion
criteria were positive testing for hepatitis C virus (HCV) or human immunodeficiency
virus (HIV) antibodies, current antiviral therapy, or liver transplantation in the 2
years before the sample was obtained.
Serological and virological determinations
HBV serological markers (HBsAg and HBeAg) and anti-HCV antibodies were tested
using  commercial  electrochemiluminescent  immunoassays  on  a  COBAS  8000
instrument (Roche Diagnostics, Rotkreuz, Switzerland). Anti-HDV antibodies were
tested using the HDV Ab kit (Dia.Pro Diagnostics Bioprobes, Sesto San Giovanni,
Italy), and anti-HIV antibodies with the Liaison XL murex HIV Ab/Ag kit (DiaSorin,
Saluggia, Italy). HBV-DNA was quantified by real-time PCR with a detection limit of
10 IU/mL (COBAS 6800, Roche Diagnostics, Mannheim, Germany). HDV-RNA was
quantified by an in-house method[26] using the HDV RNA international standard of
the  World  Health  Organization  (1st  World  Health  Organization  International
Standard for Hepatitis D Virus RNA for Nucleic Acid Amplification Techniques-
based assays; PEI code number: 7657/12), with a quantification limit of 100 IU/mL.
Amplification of HBV and HDV regions of interest by next-generation sequencing
The region of the HBX gene (nt 1255 to 1611) selected for HBV sequencing is included
in the 5’ end of all HBX transcripts. It encompasses a non-coding upstream region (nt
1255-1373) and the 5’  end of the HBX  coding region (nt  1374-1611)[23].  This latter
sequence encodes the N-terminal HBx domain (HBx amino acids 1-50), which acts as
negative  regulator  of  HBx  transactivation  and  has  an  essential  role  in  multiple
functions of the protein. The region selected for HDV genotyping covered a 360-bp
fragment of the HDV genome, from nt positions 910 to 1270. These genome regions
have both been used to respectively determine HBV and HDV genotypes in previous
studies[22,23].
For each sample, total viral nucleic acid was extracted from 200 μL of serum with
the High Pure Viral  Nucleic Acid Kit  (Roche Diagnostics,  Mannheim, Germany),
according to the manufacturer’s instructions. Molecular amplification of HBV-DNA
was performed using a 3 PCR protocol. The first-round PCR was performed using
external  primers  (forward  5’-TGTATTCCCATCCCATCATC,  and  reverse  5’-
AGWAGCTCCAAATTCTTTATAAGG, which cover the region from nt 599 to 1936)
with the following protocol: 95 ºC for 5 min followed by 35 cycles of 95 ºC for 20 s, 53
ºC for 20 s, and 72 ºC for 15 s, and finally 72 ºC for 3 min. The second- and third-round
PCRs were performed as previously described by our group[23]. By adding another
PCR to the amplification protocol described in that previous study, we were able to
increase the sensitivity limit from 3.5 logIU/mL to 2.5 logIU/mL, thereby allowing
sequencing of samples from patients with low HBV replicative activity (especially CI
and CHD samples). Amplification of the region selected for HDV genotyping was
performed by RT-nested PCR as previously described[21,22]. After amplification of the
HBV and HDV regions of interest, the final products were flanked by universal M13
sequences at both ends. In the last PCR amplification [multiplex identifier (MID)
PCR], a specific pair of primers was used, consisting of an M13 universal primer and a
MID or barcode sequence. Each individual patient sample required a different MID.
The PCR products of this amplification, also known as amplicons, were visualized as
single bands on 1.5% agarose electrophoresis gel, stained with SybrSafe DNA Gel
Stain (Invitrogen, United States) with 1 × TAE running buffer. PCR products from the
gel  were  subsequently  purified  using  the  QIAquick  Gel  Extraction  Kit  (Qiagen,
Hilden,  Germany).  Amplicon  quality  was  analyzed  using  the  Agilent  2200
TapeStation  System  with  the  D1000  ScreenTape  kit  (Agilent  Technologies,
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Waldbronn,  Germany).  Purified  DNA  from  each  sample  was  quantified  by
fluorescence using the Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies,
United States), adjusted to the same concentration, and pooled. The pools, one for
HBV (24 amplicons) and another for HDV (9 amplicons), were NGS-sequenced on the
MiSeq Platfrom (Illumina, San Diego, United States) following the manufacturer’s
protocol.
Data treatment
PCR artefacts and sequencing errors can occur when using NGS. Thus, the sequences
obtained (referred to as reads: Sequences obtained by NGS that do not always cover
the full amplicon length) require bio-informatic processing to minimize the scoring of
these errors. To this end, we developed a haplotype-centric data analysis pipeline to
exclude full  reads that  did not  meet  minimum quality  requirements,  essentially
consisting of the following steps:
Quality control of fastq files: Inspect profiles for per-site quality, read length, and
general quality-related instrument parameters.
Overlapping paired reads:  In paired-end experiments,  use FLASh[27]  to impose a
minimum of 20 overlapped base pairs (bp) with a maximum of 10% mismatches
(yield 60%-80% for 450 to 500-bp amplicons).
Discarding reads: Reads are discarded if more than 5% of bases are below a Phred
score[28] of 30, corresponding to an estimated accuracy of 99.9% (yield 75%-85%).
Demultiplexing  reads:  Demultiplexing  is  done  by  identifying  oligonucleotide
sequences at both ends within windows of expected positions in the reads (yield 70%-
85%).  First,  the  individual  MIDs  (10  oligonucleotide  sequences)  are  used  to
distinguish between samples from different patients/origins. Only one mismatch is
allowed. Second, specific primers (20 to 30-bp oligos) are used to distinguish between
different regions in the genome or different genomes, and between the two strands.
Up to three mismatches are allowed. Finally, MIDs and primers are trimmed and a
fasta file is obtained for each combination of MID, primer, and strand in the run,
where reads are collapsed to haplotypes (unique sequences covering the full amplicon
observed on the clean set of sequences) with the corresponding frequencies.
Aligning haplotypes:  In  each fasta  file  haplotypes  are  aligned to  the  wild-type
reference sequence or the master sequence (most abundant haplotype in the file) and
quality filter (yield > 90%). This quality filter consists in discarding haplotypes that do
not cover the full amplicon and those that have more than two indeterminations, three
gaps, or more than 99 differences with respect to the reference. Finally, the accepted
indeterminations and gaps are repaired as per the reference sequence.
Intersecting haplotypes: For this step, haplotypes with abundance not below 0.1% in
both strands are selected (yield 50%-60%), whereas those unique to one strand are
discarded. The coverage of haplotypes passing the filter is taken as the sum of reads
in both strands.
Final result:  All haplotypes with abundances not below 0.25% are kept. The final
haplotypes  are  called  consensus  haplotypes,  and  these  are  the  basis  for  the
downstream analysis in this study (final overall yield 15%-25%).
Genotyping
HBV and HDV genotypes were determined by NGS and phylogenetic analysis of the
amplified genome regions of both viruses. NGS allows detection of mixtures of viral
genotypes in patient samples,  which could have an impact on HBV quasispecies
complexity. The nt haplotypes aligned at 0.25% obtained by NGS were genotyped by
distance-based  discriminant  analysis  (DB  rule)[29,30].  For  this  analysis,  we  used
reference sequences of the HBV and HDV regions analyzed extracted from the full-
length genomes representative of HBV genotypes A to H and HDV genotypes 1 to 8
obtained from GenBank (Supplementary Figures 1 and 2). This analysis takes into
account the inter- and intra-class variability of each genotype. Genetic distances were
computed according to the Kimura-80 model[31].  UPGMA trees were designed to
visualize the genetic distances between sequences.
Quasispecies complexity measures
Quasispecies complexity was analyzed in HBV sequences obtained by NGS (5’ HBX
gene,  nt  1255-1611).  Multiple  alignment  displays  the  entities  (haplotypes,
polymorphic sites, and mutations) present in the viral quasispecies. In this study, six
parameters were used to describe quasispecies complexity: Number of haplotypes
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Figure 1
Figure 1  Comparison between hepatitis B virus-DNA serum levels in the three groups.aP < 0.01. CHD: Chronic
hepatitis delta; CHB: Chronic hepatitis B; CI: Hepatitis B virus chronic infection; HBV: Hepatitis B virus.
(nHpl) and number of mutations (nMuts) as incidence-based indices; Hill numbers of
order 1 and 2 (q = 1, the exponential of Shannon’s entropy and q = 2, the inverse of
Simpson’s index) as abundance-based indices; and the mutation frequency (Mf) and
nucleotide diversity (Pi) as functional indices[18,32].  The complexity parameters are
defined in Supplementary Materials.
Analysis of nucleotide substitutions
The innate immune system is suggested to contribute to HBV genetic variability
through the cytidine deaminase APOBEC (apolipoprotein B mRNA editing enzyme)
family[33], such as APOBEC3G (A3G) which promotes G–to-A, and in some cases, C-to-
T hypermutation of HBV genomes[34,35]. To infer whether this nt substitution pattern
could be associated with HBV quasispecies complexity in the groups analyzed, we
used a point mutation approach to detect bias towards a specific nt change. This
approach consists in assessing the nt changes in the sequence of haplotypes relative to
the reference sequence of the same genotype (consensus sequence of all GenBank
patterns of the same genotype used for HBV genotyping), taking into account only
one nucleotide change per position, regardless of the number of haplotypes where it
appears.
In addition, we compared the proportion of positions with a G-to-A nt change in
any haplotype (relative to the genotype reference sequence) with the proportion of
positions with an A-to-G nt change (G→A/G vs  A→G/A) between CHB, CI and
CHD. The same comparison was done for C-to-T changes: (C→T/C vs T→C/T).
Statistical analysis
Statistics were carried out using GraphPad Prism version 7.0 (GraphPad software, La
Jolla,  United  States).  All  parameters  are  expressed  as  the  median  value  and
interquartile range (IQR). For qualitative variables the chi-square test was performed.
The Kruskal Wallis and Dunn test (post hoc) were used for multiple comparisons of
independent samples. To compare the proportions of nt changes, a 2-sample test for
equality of proportions with continuity correction was performed. The Mann-Whitney
test  was used for the two-group comparisons (HBeAg+ vs  HBeAg- in CHD, and
cirrhotic vs non-cirrhotic patients). P values < 0.05 were considered significant. The
bioinformatics and biostatistics methods used in this study were reviewed by Dr.
Josep Gregori from the Liver Disease-Viral Hepatitis Laboratory of Vall d’Hebron
Hospital (Barcelona, Spain), CIBERehd research group, and Roche Diagnostics SL.
RESULTS
Patient characteristics
Clinical, virological, and serological parameters were obtained from the 24 patients.
Baseline characteristics are summarized in Table 1. Median (IQR) age was 37 (30-45
years), 58% were men, 71% were Caucasians, and the remainder were of Sub-Saharan
origin.  Regarding laboratory  characteristics,  79% were  negative  for  HBeAg and
median (IQR) alanine aminotransferase levels were 43 IU/L (31.75-118.5). HBV DNA
levels were lower in the CI [3.2 logIU/mL (2.3-3.5)] and CHD [3.4 logIU/mL (3-7.6)]
groups than in CHB [5.4 logIU/mL (3.5-7.9)] (P < 0.01 and n.s., respectively) (Figure
1).  Liver histology was available in all  cases: 2/9 patients with CHD (1 of whom
additionally had HCC), and 3/8 patients with CHB had liver cirrhosis.
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Figure 2
Figure 2  Comparison of the indices of hepatitis B virus quasispecies complexity between the three groups. A: Incidence-based indices: Number of haplotypes
(nHpl), number of mutations (nMuts) (aP < 0.05, bP < 0.01); B: Abundance-based indices: Hill numbers (Hill q = 1 and Hill q = 2) (cP < 0.05); C: Functional-based
indices: Mutation frequency (Mf) and nucleotide diversity (Pi). One outlier value in the CI group was eliminated in the representation of Mf results, but this value was
included in the statistical comparisons. nHpl: Number of haplotypes; nMuts: Number of mutations; Mf: Mutation frequency; Pi: Nucleotide diversity; CHD: Chronic
hepatitis delta; CHB: Chronic hepatitis B; CI: Hepatitis B virus chronic infection.
Analysis of NGS sequences obtained and genotyping results
After applying the quality filters, 791036 sequences from the HBV target region were
obtained from the 24 serum samples, yielding a median (IQR) of 26459 (17649-44852)
sequences per patient. Regarding HDV, 287541 sequences were obtained from the 9
samples, yielding a median (IQR) of 17609 (14475-22677) sequences per patient. HBV
genotyping showed that in the region analyzed (nt 1255 to 1611),  15/24 patients
(62.5%) had a complex mixture of genotypic variants, mainly A/D/C. None of the
patients included showed genotype B, G, or H haplotypes. With regard to the HDV
region analyzed (nt 910 to 1270), 7/9 (78%) CHD patients were classified as genotype
HDV-1, whereas 2/9 (11%) were HDV-2 and HDV-6, respectively.
Characterization of HBV quasispecies complexity
To analyze HBV quasispecies complexity data from samples of notably different
coverage, samples were made comparable by down-sampling and fringe trimming to
a common coverage of 6000 reads, retaining haplotypes at a frequency above 0.2%
with 95%CI. Quasispecies complexity in the HBV target region was evaluated using
six parameters. Of note, all CHB and CI patients were HBeAg-negative, whereas 5/9
CHD patients were HBeAg-positive. The complexity of the viral population in the
preCore/Core region of the viral genome has been reported to differ between HBeAg-
positive and -negative HBV mono-infected patients[36]. To determine whether HBeAg
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Table 1  Baseline characteristics according to the clinical stage of hepatitis B virus or hepatitis B virus/hepatitis delta virus infection
Total, n = 24 Chronic HBV infection, n =7
Chronic hepatitis B, n =
8
Chronic hepatitis delta, n =
9 P value
Age, yr, median (IQR) 36.5 (30.75-48) 40 (33.5-60.5) 35.5 (32.75-42) 38 (30-41) NS
Male, n (%) 14 (58) 4 (57) 4 (50) 6 (67) NS
Ethnic group, n (%)
Caucasian 17 (71) 5 (71) 5 (62) 7 (78) NS
Sub-Saharan 7 (29) 2 (29) 3 (38) 2 (22)
ALT, IU/L, median (IQR) 43 (31.75-118.5) 27 (16-30.5) 60 (44.25-118.5) 80 (39-138) 0.0007
HBeAg-, n (%) 19 (79) 7 (100) 8 (100) 4 (44) 0.005
HBsAg, logIU/mL, median (IQR) 3.8 (3.5-4.1) 3.6 (2.6-3.9) 3.6 (3.4-3.7) 4.1 (3.8-4.5) 0.0152
HBV DNA, logIU/mL, median
(IQR)
3.5 (3.2-5.4) 3.2 (2.8-3.4) 5.4 (3.9-6.2) 3.4 (3.2-4) 0.0038
HDV RNA, logIU/mL, median
(IQR)
5.5 (4.3-5.5) -
IQR: Interquartile range; ALT: Alanine aminotransferase; HBeAg: Hepatitis B e-antigen; HBsAg: Hepatitis B virus surface antigen; HBV: Hepatitis B virus;
NS: Not specified; HDV: Hepatitis delta virus.
status had an effect on quasispecies complexity in the HBX 5’ region in CHD patients,
the six parameters used to assess this factor were compared between HBeAg-negative
and –positive CHD patients, but no statistically significant differences were found
(Table 2).  Thus,  the patients’  HBeAg status was not considered to be a potential
interfering factor.  In addition,  we compared these complexity indices between 5
patients with liver cirrhosis, including 2 CHD and 3 CHB, and 19 patients without
progression to severity. No significant differences were found (Table 3).
Comparison  between  HBV  mono-infection  (CHB  and  CI)  vs.  CHD  (HBeAg-
negative and HBeAg-positive) in two-group tests showed no significant differences in
the incidence, abundance, or functional indices related to quasispecies complexity.
However, significant differences were found between CHB and CI in incidence and
abundance-that is, median nHpl (IQR), CHB 31 (12-75, 34.75) vs CI 60 (47.5-65) (P =
0.011), nMuts, 39 (20.75-69.25) vs 105 (97.5-112.5) (P < 0.01), and Hill numbers of order
1, 6.70 (1.37-9.43) vs 21.54 (18.99-22.14) (P = 0.012), and 2, 2.81 (1.11-4.57) vs 9.86 (8.37-
11.22) (P = 0.027)-with the CI quasispecies showing greater complexity than that of
CHB  (Figure  2).  No  statistically  significant  differences  were  observed  for  the
functional  indices  (Mf and Pi),  which are  sensitive  to  the number of  differences
between the  different  haplotypes,  although the  results  showed a  trend towards
greater complexity in CI and CHD than in CHB patients (Figure 2C). Regarding the
effect of HDV on the HBV quasispecies, the most interesting finding was that the HBV
viral populations in CHD and CI showed a similar trend, with greater complexity
(higher  incidence,  abundance  and functional  values)  than that  of  CHB patients,
although only Hill numbers of order 2 showed a statistically significant difference,
CHB 2.81 (1.11-4.57) vs CHD 8.87 (6.56-11.18) (P = 0.038) (Figure 2). There were no
significant differences in any HBV complexity indices between CHD and CI patients.
Types of nucleotide changes in HBV sequences
All types of nt changes were computed in the three patient groups. As the patterns of
nt changes varied between the different genotypes (data not shown), we only took
into account genotype A (Figure 3A) and D (Figure 3B) haplotypes, which were the
most  abundant  in  our  samples  [genotype  A  511/1065  haplotypes  (47.98%)  and
genotype D 264/1065 haplotypes (24.79%)], for the comparisons. In this analysis we
found that the pattern of nt changes in genotype A haplotypes (Figure 3A) differed
from those in genotype D (Figure 3B). The nt changes G-to-A and C-to-T, which are
characteristic of the modifications introduced by the A3G enzyme, were higher in
CHD and CI than in CHB patients in genotype A haplotypes (Figure 3A), but not in
genotype D (Figure 3B). We then compared the proportion of G-to-A vs A-to-G nt
changes and C-to-T vs T-to-C in genotype A and D haplotypes by group to investigate
bias in the nt change pattern, which could be associated with the effect of A3G. There
were no significant differences in these changes in either genotype A or genotype D in
CHD patients.  The results  in CHB and CI were dependent on HBV genotype.  In
genotype A haplotypes, the proportion of C-to-T nt changes was higher than T-to-C in
the  CI  group  (0.22  vs  0.07  respectively,  P  <  0.01),  whereas  in  genotype  D  the
proportion of G-to-A nt changes was higher than A-to-G in the CHB group (0.20 vs
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Table 2  Comparison of hepatitis B virus quasispecies complexity indices between hepatitis B e-antigen-negative and hepatitis B e-
antigen-positive chronic hepatitis D patients
CHD HBeAg-negative (n = 4) CHD HBeAg-positive (n = 5) P value
nHpl, median (IQR) 42 (36-47) 42 (27-54) 1.0
nMuts, median (IQR) 97.5 (72.5-104) 100 (18-100) 1.0
Mf, median (IQR) 0.039 (0.027-0.045) 0.035 (0.002-0.041) 0.4127
Pi, median (IQR) 0.047 (0.033-0.052) 0.046 (0.004-0.049) 0.5556
Hill number (q = 1), median (IQR) 17.29 (14.46-20.49) 16.62 (10.06-20.96) 1.0
Hill number (q = 2), median (IQR) 10.03 (8.29-12.11) 8.15 (6.56-10.42) 0.5556
IQR: Interquartile range; CHD: Chronic hepatitis D patients; nHpl: Number of haplotypes; nMuts: Number of mutations; Mf: Mutation frequency; Pi:
Nucleotide diversity.
0.04 respectively, P = 0.025).
DISCUSSION
Clinical and experimental data support the existence of interference between HDV
and HBV. Although several hypothesis have been raised to define the interactions
between these viruses[37], the molecular mechanisms through which HDV affects HBV
remain elusive. In the clinical setting, most HBV/HDV co-infected patients show a
pattern of HDV dominance, with a significant decrease in HBV-DNA viral load when
compared to that of mono-infected patients[12,38,39]. In accordance with these data, our
results showed lower HBV-DNA levels in HDV-infected patients, with values similar
to those in the chronic HBV infection group.
The viral population analyses carried out found no significant differences in the
complexity of the HBV quasispecies between the total of patients with HBV mono-
infection and patients with CHD. These results would seem to suggest that HBV
quasispecies complexity is unaffected by the presence of HDV. However, when the
clinical phases of the disease were taken into account, HBV quasispecies complexity
was found to be greater (significant in incidence and abundance-based indices and
non-significant in functional indices) in CI than in CHB patients. Surprisingly, the
viral population was more complex in the group with lower replication. This may
indicate  that  the  higher  incidence  of  mutations  in  the  5’  of  HBX,  distributed  in
different haplotypes in CI patients could cause HBV replication to be closer to the
quasispecies error threshold, that is, the point beyond which the mutation rate is so
high that the genetic information carried by the replicating genome is lost[40]. In this
sense, it should be taken into account that HBx is essential for HBV replication. For
this reason, it seems logical to associate HBX variability with HBx functionality, which
would affect HBV replication and result in the low HBV replication levels observed in
the CI stage of HBV infection.
As to the interaction between HDV and HBV, it seems that CHD drives the HBV
quasispecies to a situation similar to that observed in CI patients: Lower replication
level and higher HBX quasispecies complexity than CHB patients. Two hypotheses
could explain the mechanism by which HDV enhances HBV quasispecies complexity.
The first is activation of the host innate immune response under the effect of HDV
stimulation[39,41,42]. A3G activity, which provides broad innate immunity[34,43], could
therefore be responsible for the hyper-mutation of HBV genomes. To investigate this
possibility,  we analyzed nucleotide changes in the CHB, CI,  and CHD groups to
determine whether there was some bias in favor of those produced by A3G. Although
HDV  activates  the  immune  system,  we  did  not  find  a  hyper-mutation  pattern
associated  with  A3G.  Nonetheless,  this  hypothesis  should  be  more  extensively
analyzed in further, more specific studies, and it could be extended to other innate
immunity enzymes.
The second hypothesis postulates a possible interaction between HDAg and RNA
pol II, which could affect the replicative capacity and functionality of this enzyme. As
Yamaguchi et al[14]  reported, HDAg not only increases the elongation rate,  it  also
reduces transcriptional fidelity by interacting with and loosening the RNA pol II
clamp. This would increase the error rate, introduce a larger number of mutations,
and give rise to a more complex quasispecies. This mechanism has been suggested to
explain the extremely high mutation rate  that  occurs  in  HDV replication[22,44].  In
addition  to  HDV,  this  loss  of  fidelity  would  also  affect  HBV transcription.  It  is
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Table 3  Comparison of hepatitis B virus quasispecies complexity indices between patients with
and without liver cirrhosis
Cirrhotic (n = 5) Non cirrhotic (n = 19) P value
nHpl, median (IQR) 34 (28.5-44) 42 (27-60) 0.5456
nMuts, median (IQR) 28 (21-95.5) 100 (50-105) 0.2130
Mf, median (IQR) 0.035 (0.0019-0.0905) 0.03715 (0.0025-0.0440) 0.8311
Pi, median (IQR) 0.0223 (0.00347-0.0445) 0.0434 (0.0044-0.0481) 0.3937
Hill number (q = 1), median (IQR) 10.06 (6.7-18.69) 16.62 (7.02-22.02) 0.4994
Hill number (q = 2), median (IQR) 6.56 (2.81-10.23) 8.37 (3.05-10.42) 0.7223
IQR:  Interquartile  range;  nHpl:  Number  of  haplotypes;  nMuts:  Number  of  mutations;  Mf:  Mutation
frequency; Pi: Nucleotide diversity.
important to keep in mind that HBV cccDNA is the template for transcription of all
viral mRNA including pregenomic RNA, essential for progeny production, and that
pregenomic  RNA transcription from both  cccDNA and integrated HBV DNA is
mediated by the host RNA pol II[45,46]. This effect of HDV on RNA pol II could also
affect cellular mRNAs, thereby worsening cell homeostasis, and this could be linked
to the poorer prognosis of HDV hepatitis when compared to the other viral hepatitis.
To test this possibility, NGS studies investigating the complexity of cellular mRNAs in
CHD are needed.
Thus, hyper-mutation due to the innate immune system and loss of RNA pol II
fidelity by the effect of HDV could have an impact on HBV DNA synthesis, which,
along with the error rate of the HBV polymerase itself, could give rise to a situation
similar to that seen in CI patients, driving the HBV quasispecies closer to its error
threshold. However, we would expect to find significant differences between CHD
and CHB in other complexity indices in addition to Hill  numbers (q = 2)  in this
scenario. Hence, larger samples taken at different time points and other regions of the
genome should be analyzed in future studies to confirm these results.
In this line, 2 recent studies[47,48] investigated HBV sequence variation in the viral
genome surface (S)  ORF (encoding HBsAg) in large patient cohorts.  The authors
compared consensus sequences obtained from HBV/HDV infected vs HBV mono-
infected patients. Both studies concluded that HDV can exert selective pressure over
some positions  of  the  S  ORF,  constraining  HBV evolution.  In  the  light  of  these
findings, it would be interesting to assess the effect of HDV on the HBV quasispecies
in the S ORF and compare it with the effect in other regions of the viral genome, such
as that analyzed in the present study. These efforts illustrate the relevance of studies
investigating the HBV quasispecies in HDV superinfected or coinfected patients to
deepen current knowledge on the interference between HDV and HBV. In addition,
cellular and animal models of HBV/HDV infection[42,49]  enable in vitro  and in vivo
functional  studies  to  test  whether  the  presence  of  HDV  has  an  effect  on  HBV
replication and genetic diversity.
Of note, the patients included in this study had to have HBV replication at high
enough levels  for  amplification by our PCR protocol.  This  obliged us to include
HBeAg-positive  CHD patients  (5/9),  whose  numbers  are  limited  in  HBV/HDV
infection. We believed it was necessary to determine whether HBeAg status may have
had  an  effect  on  quasispecies  complexity,  as  we  found  a  more  complex  viral
population in the preCore/Core region of the HBV genome in HBeAg-negative than
HBeAg-positive CHB patients in a previous analysis[36]. However, the present study,
focusing on the 5’  region of  HBX  (nt  1255-1611),  showed that  HBV quasispecies
complexity was similar in HBeAg-positive and -negative CHD. These differences may
be  related  to  the  regions  studied:  the  5’  region  of  HBX  does  not  have  a  direct
relationship with HBeAg status; hence, it would not have a significant influence on
HBV quasispecies complexity in this region. Thus, as HBeAg status did not seem to
significantly affect HBV quasispecies complexity in the 5’ HBX region, we were able
to compare all CHD patients (both HBeAg-positive and HBeAg-negative) with CHB
and CI patients. Another factor that could be related to HBV quasispecies complexity
is liver disease progression to cirrhosis or HCC, which had occurred in 5 patients
(both CHB and CHD) included in this study. Comparison of quasispecies complexity
between these  patients  and the  19  who did  not  progress  to  severity  showed no
statistically significant differences. Nonetheless, although HBeAg status and more
severe  disease  stage  did  not  affect  HBV quasispecies  complexity  in  our  sample,
analysis of larger patient groups is needed to define the actual role of these virological
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Figure 3
Figure 3  Nucleotide change patterns. A: Genotype A substitution rates by group; B: Genotype D substitution rates by group. aP < 0.05, bP < 0.01. CHD: Chronic
hepatitis delta; CHB: Chronic hepatitis B; CI: Hepatitis B virus chronic infection.
and clinical factors.
In summary, this study provides the first data on the influence of HDV on HBV
genetic diversity in the HBX gene, obtained using NGS. Our results showed that in
HBV stages with lower replication (CHD and CI), the HBV quasispecies in the 5’end
of HBX exhibited a trend toward higher complexity than in CHB. This was mainly
evident in terms of incidence and abundance, that is, a higher incidence of mutations,
distributed in different haplotypes.  The mechanisms associated with this greater
complexity are unknown, but two hypotheses could explain them: involvement of the
innate immune response or HDAg interaction with RNA pol II,  which should be
explored in greater depth.
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ARTICLE HIGHLIGHTS
Research background
Hepatitis delta virus (HDV) causes the most severe form of chronic viral hepatitis in persons
simultaneously infected with hepatitis B virus (HBV). In longitudinal clinical studies, HDV
infection has been associated with a considerable temporary or permanent reduction in HBV
viral load, whereas HBV surface antigen levels are usually high. Thus, beyond the interaction
with HBV envelope proteins, there are other mechanisms by which HDV inhibits HBV-DNA
replication.
Research motivation
To date, little information has emerged on the interaction between HDV and HBV. In this study,
we investigated whether HDV can affect the complexity of the HBV quasispecies, and proposed
possible mechanisms by which it may do so, to further characterize the interaction between these
two viruses.
Research objectives
Considering the essential role of the HBV X protein (HBx) on viral replication, the aim of this
study was to analyze the 5’ end of the hepatitis B X gene (HBX) coding region and its upstream
non-coding  region  (nt  1255-1611)  by  next-generation  sequencing  (NGS)  to  evaluate  HBV
quasispecies complexity between chronic hepatitis delta (CHD)-infected patients and chronic
HBV mono-infected patients [HBV chronic infection (CI) and chronic hepatitis B (CHB)].
Research methods
The HBX  5’  end region, nucleotide (nt)  1255-1611, was PCR-amplified for subsequent NGS
(MiSeq,  Illumina,  United  States)  in  7  CI,  8  CHB,  and  9  CHD  patients.  HBV  quasispecies
complexity in the region analyzed was evaluated using incidence-based indices [number of
haplotypes (nHpl) and number of mutations (nMuts)], abundance-based indices (Hill numbers
of order, q = 1 and q = 2) and functional indices [mutation frequency (Mf) and nt diversity (Pi)].
The  pattern  of  nt  changes  was  evaluated  to  investigate  the  cause  of  HBV  quasispecies
complexity.
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Research results
HBV  quasispecies  complexity  was  significantly  higher  in  the  CI  group  than  in  CHB  for
abundance (Hill numbers q = 1 and q = 2) and incidence (nHpl and nMuts). In CHD, the HBV
quasispecies  showed a trend towards higher  complexity similar  to  that  of  CI  patients.  No
significant differences were observed in Mf or Pi between the groups, although CI and CHD
showed a trend towards greater quasispecies complexity than CHB patients. The proportion of
G-to-A vs. A-to-G and C-to-T vs. T-to-C nt changes in genotype A and D haplotypes by group
did not provide conclusive evidence of a hyper-mutation pattern associated with the innate
immune system enzyme APOBEC3G.
Research conclusions
The  HBV  quasispecies  showed  a  trend  to  higher  complexity  in  groups  with  lower  viral
replication (CHD and CI) than in the higher-replicating CHB patients. This could indicate that
HDV has an effect  on the 5’  HBX  sequence,  increasing HBV quasispecies complexity.  Two
different mechanisms are proposed to explain how HDV can change the HBV quasispecies:
hypermutation by activation of the innate system through HDV stimulation or loss of RNA pol II
fidelity  due  to  its  interaction  with  hepatitis  delta  antigen.  Further  studies  are  needed  to
determine the clinical impact of the increased HBV quasispecies complexity in CHD patients,
which may be of help to devise new therapy strategies.
Research perspectives
CHD drives  the  HBV quasispecies  to  a  situation  similar  to  that  found in  HBV CI:  Lower
replication level and higher HBX quasispecies complexity than in CHB patients. Further studies
are needed to characterize the mechanisms by which HDV acts on the HBV quasispecies, which
may include the innate immune system or RNA pol II fidelity.
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